Source comparison
How to Use Thymosin Alpha-1 for Immune Modulation Protocol: Peptide Comparison
Thymosin Alpha-1 Toll-like receptor activation, IL-2 upregulation, T-cell differentiation 1.6-3.2mg subcutaneous twice weekly 2-3 hours (circulating); 48-72 hours (downstream signalling) CD4/CD8 ratio normalisation, NK cell activity +25-40%, Th1 cytokine shift
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- Toll-like receptor activation, IL-2 upregulation, T-cell differentiation
- 1.6-3.2mg subcutaneous twice weekly
- 2-3 hours (circulating); 48-72 hours (downstream signalling)
- CD4/CD8 ratio normalisation, NK cell activity +25-40%, Th1 cytokine shift
- Gold standard for T-cell recalibration research. Evidence base strongest in chronic viral infections and cancer immunotherapy support
- Thymalin
- Thymic peptide complex, broader polypeptide action on immune maturation
- 5-10mg intramuscular daily for 5-10 days, then maintenance cycles
- 4-6 hours
- Generalised immune function improvement, thymus regeneration markers
- Broader but less targeted than Thymosin Alpha-1. Used when general immune support rather than specific T-cell modulation is the research goal
- MK 677
- Growth hormone secretagogue, indirect immune support via IGF-1 elevation
- 10-25mg oral daily
- 24 hours
- Modest increases in lymphocyte proliferation, wound healing acceleration
- Not a direct immune modulator. Effects are secondary to growth hormone axis stimulation; better suited for metabolic research than targeted immunology